EXPERIMENTAL AND THERAPEUTIC MEDICINE 20 26 2020 Abnormal metabolic processes involved pathogenesis nonalcoholic fatty liver disease Review MINGMEI SHAO ZIXIANG YE YANHONG QIN TAO WU Institute Interdisciplinary Integrative Medicine Research Shanghai University Traditional Chinese Medicine Shanghai 201203 PR China Received November 26 2019 Accepted May 28 2020 DOI 103892etm20209154 Abstract Nonalcoholic fatty liver disease NAFLD common chronic liver diseases lead liver cirrhosis liver cancer severe cases In recent years incidence NAFLD increased substantially The trend continued increase key point concern health systems NAFLD associated metabolic abnormalities caused increased visceral obesity including insulin resistance diabetes mellitus hypertension dyslipidemia atherosclerosis systemic microinflam mation Therefore pathophysiological mechanisms NAFLD clarified develop new drug treatment strategies Recently researchers conducted numerous studies pathogenesis NAFLD identified important regulatory factors potential molecular mechanisms providing new targets theoretical basis treatment NAFLD However pathogenesis NAFLD extremely complex involves interrelation ship influence multiple organs systems Therefore Correspondence Dr Tao Wu Institute Interdisciplinary Integrative Medicine Research Shanghai University Traditional Chinese Medicine 1200 Cailun Road Shanghai 201203 PR China Email wutao001827163com Abbreviations AAAs aromatic amino acids Akt protein kinase B BCAAs branchedchain amino acids Cl chloride ions ERS endoplasmic reticulum stress FFA free fatty acids FGF21 fibroblast growth factor 21 FXR farnesoid X receptor GLP1 glucagonlike peptide 1 LOXL2 lysyl oxidaselike 2 LXR liver X receptor NAFLD nonalcoholic fatty liver disease NASH nonalcoholic steatohepatitis NPC1L1 Niemannpick c1like 1 HSC hepatic stellate cells IL6 interleukin6 IR insulin resistance IRS1 insulin receptor substrate 1 PNPLA3 patatinlike phospholipase domain containing 3 PPAR peroxisome proliferatoractivated receptor ROS reactive oxygen species SREBP sterol regulatory elementbinding protein T2D type 2 diabetes TG triglyceride TMAO trimethylamineNoxide TNFα tumor necrosis factorα VLDL lowdensity lipoprotein Key words nonalcoholic fatty pathogenesis lipid mechanism liver disease metabolism condition explored In present review abnormal metabolic process including glucose lipid amino acid bile acid iron metabolism reviewed It concluded NAFLD associated imbalanced metabolic network involves glucose lipids amino acids bile acids iron lipid metabolism core metabolic process The current study aimed provide evidence hypotheses research clinical treatment NAFLD Contents 1 Introduction 2 Glucose metabolism NAFLD 3 Lipid metabolism NAFLD 4 Amino acid metabolism NAFLD 5 Bile acid metabolism NAFLD 6 Iron metabolism NAFLD 7 Conclusion 1 Introduction Nonalcoholic fatty liver disease NAFLD caused excess fat deposits liver nonalcoholic factors 1 high fat diet high cholesterol diet sedentary lifestyle The condition represents range liver diseases nonalcoholic fatty liver known simple steatosis nonalcoholic steatohepatitis NASH fibrosis cirrhosis 12 NAFLD characterized metabolic syndrome MS features including altered glucose lipid metabolism imbalanced amino acid homeostasis increased bile acid excess hepatic iron 3 Due increased inci dence obesity associated MS NAFLD common liver disease worldwide The global prevalence NAFLD currently estimated 252 4 Notably radical changes Chinese lifestyle sedentary behaviour hypercaloric diet prevalence NAFLD China increased 329 2018 5 Therefore clarifica tion pathophysiological mechanisms NAFLD necessary development pharmacological treatment strategies The pathogenesis NAFLD remains unclear widely accepted follow multiplehit hypothesis 2 SHAO et al ABNORMAL METABOLISM INVOLVED IN NAFLD According hypothesis NAFLD complex disease pathogenesis involves diet genetic environment metabolic factors progress different stages occurrence development NAFLD 6 Elevated levels circulating free fatty acids FFAs combined insulin resistance IR excessive accumulation triglyc erides liver cells serve major role development NAFLD 7 Additionally lipid accumulation responsible oxidative stress inflammatory response lipotoxicity predisposing patients progressive liver injury 8 IR lipotoxicity inflammatory response genetic polymorphisms adipokines intestinal flora affect pathogenesis NAFLD 8 However interaction mecha nisms changes occurrence development NAFLD remain determined Since NAFLD involves multiple metabolic pathways Fig 1 attention paid abnormal metabo lism worsen metabolic disorders 913 In present review abnormal metabolism NAFLD including glucose lipid amino acids bile acids iron metabolism summarized aim provide evidence hypotheses NAFLD diagnosis possible therapeutic strategies 2 Glucose metabolism NAFLD An important factor affecting NAFLD hyperglycemia stimulates insulin secretion increases triglyceride synthesis liver resulting increase triglycerides blood gradual accumulation liver form fatty liver Prolonged chronic hyperglycemia causes hepatocel lular damage alters structure function pancreatic β cells causes IR inducing accelerating occurrence progression NAFLD 14 Fructose metabolism similar glucose metabolism lead triglyceride generation The main difference processes glucose primarily metabo lized glucose kinases hexokinases fructose mainly metabolized fructose kinases 15 Fructose metab olism liver contributes increased hepatic lipogenesis inhibits mitochondrial βoxidation longchain fatty acids Numerous patients NAFLD insufficient anti oxidant capacities inhibit fructose metabolism 16 A recent study demonstrated dietary fructose promoted hepatic lipogenesis microbiotaderived acetate 17 Insulin closely associated carbohydrate metabo lism disorder NAFLD facilitates formation fat inhibits lipases participates glucose homeo stasis hepatic glycogen synthesis 18 IR important pathophysiological basis carbohydrate metabolism disor ders consistent NAFLD development Glucagonlike peptide 1 GLP1 stimulates insulin secretion suppresses glucagon strictly glucosedependent manner 19 Furthermore GLP1 serves role coordination fibro blast growth factor 21 FGF21 20 GLP1 FGF21 affect insulin function secretion respectively 21 Additionally lysyl oxidaselike 2 LOXL2 expression directly propor tional severity IR LOXL2 inhibitors prevent NASH progressing fibrosis 22 IR major feature NAFLD lead type 2 diabetes T2D hyperinsulinemia glucose intolerance additional effects glucose metabo lism 23 The regulatory mechanisms IR involve chloride ions Cl insulin signaling Cl common affluent anions living organisms Chloride channels ClCs func tion type permeable channel protein encoded regulated genes ClC family ClC2 member ClCs family Fatty deposits abundant expression ClC2 activated fatty acids liver induces IR 24 The transduction insulin signaling regulated insulin receptor substrate 1 IRS1 25 When insulin binds insulin receptors IRS1 phosphorylated tyrosine 608612 activate insulin signaling pathway However phosphorylation IRS1 serine 307312 suppresses glucose absorption leads IR inhibits insulin signaling Additionally dysregulation protein kinase B2 Akt2 signaling pathways reported NAFLD Akt2 facilitates glucose uptake suppresses IR Furthermore Akt2 inhibited fetuinA type hepato kine synthesized liver inhibits insulin receptor tyrosine phosphorylation skeletal muscles activity Akt2 reduce glucose uptake 26 Increasing evidence demonstrated disordered cellular Cl concentrations associated lipid accumulation high blood pressure atherosclerosis 2728 Notably chloride channel 2 CIC2 inhibition alleviates high fat dietinduced hepatic steatosis inflammation fibrosis 24 GLP1 GLP1 antihyperglycemic hormone induces pancreatic β cells secrete insulin Trevaskis et al 29 demon strated GLP1 receptor agonists significantly improve metabolism biochemical histopathological indicators NASH mice Bernsmeier et al 30 reported patients NAFLD exhibited IR insufficient GLP1 secretion Furthermore Chellali et al 31 demonstrated patients NAFLD T2D NAFLDT2D generally exhibited IR compared controls plasma GLP1 levels obviously lower patients NAFLD T2D NAFLDT2D GLP1 receptor agonists approved T2D treatment increasing number previous studies demonstrated effective NAFLD 3235 FGF21 FGF21 member fibroblast growth factor family hormonelike endocrine factor secreted liver serves critical role maintaining homeostasis glycolipid metabolism 36 Li et al 37 reported serum FGF21 levels fatty liver index 38 known score associated steatosis presence specificity early diagnosis NAFLD FGF21 primarily produced liver specifically acts liver fat islet cells FGF21 reduce body weight wholebody fat mass liver triglyceride content increases fat utiliza tion energy expenditure improves glucose tolerance insulin sensitivity liver adipose tissue 39 FGF21 independent insulin regulates blood glucose blood lipid 39 FGF21 reduce glucose levels triggering hypoglycemia increase glucose uptake brown fat browning white fat increase overall energy consumption As metabolic regulator FGF21 signifi cantly reduces expression key genes involved lipid metabolism including stearoylcoenzyme A desaturase 1 EXPERIMENTAL AND THERAPEUTIC MEDICINE 20 26 2020 3 Figure 1 The metabolic network NAFLD NAFLD nonalcoholic fatty liver disease GLP1 glucagonlike peptide 1 IR insulin resistance LOXL2 lysyl oxidaselike 2 FXR farnesoid X receptor LXRs liver X receptors PNPLA3 patatinlike phospholipase domain protein 3 BCAAs branched chain amino acids NPC1L1 NiemannPick c1like 1 ROS reactive oxygen species positive regulation negative regulation glucokinase reduces fat syntheses upregulates expression key genes involved lipolysis including leptin receptor insulinlike growth factor binding protein 2 promotes fat decomposition energy metabolism reducing accumulation fat liver tissue restoring normal liver function 40 LOXL2 IR associated severity liver fibrosis main determinant NAFLD prognosis 4142 LOXL2 enzyme promotes network collagen fibers extra cellular matrix 43 LOXL2 expression strongly correlated steatosis severity fibrosis Hepatic LOXL2 upregulation specifically detected patients NAFLD T2D progressing advanced fibrosis 22 Ikenaga et al 44 reported LOXL2 expression virtu ally absent healthy livers strongly induced fibrotic livers LOXL2 inhibition promoted fibrosis reversal Therefore LOXL2 antibodies potential treatment liver fibrosis A monoclonal antibody LOXL2 simtuzumab developed currently phase II trials 45 3 Lipid metabolism NAFLD NAFLD characterized significant accumulation lipids triglyceride TG FFAs cholesterol hepatocytes serum indicating altered lipid metabo lism crucial pathogenesis NAFLD Excess TG serum FFAs common NAFLD Excess TG accu mulate novo hepatic lipogenesis dietary fat supply FFAs accumulate lipolysis visceral adipose tissue 46 FFAs participate fatty acid βoxidation endoplasmic reticulum stress ERS response lysosomal dysfunction cell death mitochondrial pathway induce NAFLD 47 Trans fatty acids TFAs facilitate lipogenic gene expression hepatic lipid accumulation causing severe steatosis regulating Kupffer cells 48 There main pathways lipid metabolism The βoxidation liver FFAs binding lowdensity lipoproteins VLDLs liver 4950 When lipid synthesis pathways increase IR develops liver lesions generated However promoting βoxidation inhibiting synthesis lipids IR liver lesions alleviated Additionally certain lipids bind VLDL transported liver In smooth endoplasmic reticulum SER TGrich VLDL transfused secreted transported liver secretory vesicles Excessive liver lipids induce ERS SER increase production inflammatory cytokines Therefore variety lipid metabolismrelated regulatory factors closely associated NAFLD However regulatory factors effective target treatment NAFLD remains elucidated research 5152 Inflammatory cytokines Numerous previous studies demonstrated inflammatory cytokines serve key roles progression steatosis NASH 5354 Zahran et al 55 reported tumor necrosis factor TNFα levels elevated patient population NASH compared controls Furthermore Bocsan et al 56 demonstrated plasma interleukin IL6 TNFα levels significantly higher patients NASH compared controls TNFα produced hepatocytes infil trating immune cells Moreover stimulates liver steatosis turn increases serum TG levels 57 Additionally TNFα activates Kupffer cells turn stimulate liver fibrosis NAFLD progression 58 IL6 primarily secreted adipose tissue important mediator fatty acid metabolism serves paradoxical role liver While hepatic IL6 signaling pathway protective effect development liver steatosis promote liver inflammation 59 4 SHAO et al ABNORMAL METABOLISM INVOLVED IN NAFLD Patatinlike phospholipase domain containing 3 PNPLA3 PNPLA3 secretory adipose factor widely expressed human tissues particularly liver adipose tissues 60 In 2008 Romeo et al 61 conducted genomewide associa tion analysis screen pathogenic genes NAFLD A group nonsynonymous sequence variations including Hispanic AfricanAmerican EuropeanAmerican participants n9229 selected polymorphic PNPLA3 rs738409 liver tissue identified order identify genetic variants contributing differences hepatic fat content Increased concentrations fat liver inflammation highly associated Homeostatic Model Assessment IR mechanism liver damage associated intrahepatic lipid deposition Additionally Wang et al 62 studied 768 patients Han Chinese population confirmed association PNPLA3 rs738409 increased risk NAFLD population emphasizing effects NAFLD multiple ethnic groups Several previous studies metaanal ysis demonstrated genetic variation PNPLA3 increases risk NAFLD European Chinese populations 63 Numerous previous studies reported PNPLA3 gene polymorphism associated increase liver fat content liver inflammation 6365 As enzyme bidirec tional ability regulate fat metabolism PNPLA3 promotes lipid synthesis involved ectopic lipid deposition IR key factors pathogenesis NAFLD PNPLA3 leads pathogenesis NAFLD 66 Peroxisome proliferatoractivated receptors PPARs PPAR ligandactivated transcription factors control different aspects lipid catabolism The PPAR subtype PPARα highly expressed liver promotes genes regulate βoxidation fatty acids Thus inducing PPARαregulated lipid catabolic pathway genes enhance NAFLD Another subtype PPARγ nuclear receptor regulates insulin sensitivity lipid metabolism molecular target insulin sensitizing agents PPARγ expressed hepatic stellate cells HSCs influence perilipin expression regulates lipid droplet metabolism The activation HSCs largely contributes fibrogenesis process 67 Sterol regulatory elementbinding proteins SREBPs SREBPs control cholesterol TGs fatty acids SREBP1c subtype predominantly localized adult liver required simple steatosis fasting Overexpressed SREBP1c leads excessive TG accumulation liver ultimately NAFLD Thus inhibition SREBP1c preventive approach 68 PPARα SREBP1 key determinants NAFLD 69 SREBP2 important nuclear transcription factor regulates cellular cholesterol homeostasis Its activa tion promotes accumulation hepatocyte cholesterol facilitating cholesterol synthesis uptake suppressing reverse cholesterol transport 70 Additionally SREBP2 predicts NASH widely impairs pancreatic β cell func tion tissue insulin sensitivity adipokine lipoprotein responses fat uptake Thus elevated SREBP2 increases prevalence NAFLD cardiovascular diseases Abnormal SREBP2 activation reversed depleting cholesterol adipocytes 71 Adiponectin Adiponectin insulinsensitizing adipocyto kine adipocytederived antiinflammatory mediator acts receptors elicit AMP kinase signaling 72 Adipose tissue major site endogenous adiponectin production Previous research demonstrated plasma levels adiponectin significantly diminished visceral obesity states IR NASH T2D athero sclerosis 7374 Adiponectin agonists represent potential alternative therapeutic approaches NAFLD treatment Leptin Leptin hormone secreted mainly adipocytes white adipose tissue product obese gene 75 Perfield et al 76 reported novo lipogenesis induced hepatic mitochondria reduced inhibited leptindeficient NAFLD mice ZelberSagi et al 77 demon strated leptin levels significantly higher patients NAFLD compared patients NAFLD 7 years followup Furthermore Polyzos et al 78 revealed serum leptin levels patients NAFLD higher compared controls serum leptin levels asso ciated increased severity NAFLD However lack leptin lead liver steatosis reversed leptin replacements 79 excessive leptin cause liver inflammation fibrosis Liver X receptors LXRs As members metabolic nuclear receptor superfamily LXRs influence regulation cholesterol absorption conveyance transportation excretion 80 Research demonstrated LXR activation regulates cholesterol homeostasis induces antiinflammatory effects increases insulin sensitivity 81 Inhibiting liver LXR transcriptional activity NAFLD effectively reduces liver steatosis inflammation fibrosis However research LXR highly expressed livers patients NAFLD increases severity NAFLD LXR expression directly proportional liver lipid deposition 82 However uncertainty LXR activation inhibition beneficial NAFLD treatment hindered development LXRrelated drugs 83 Plin2 Plin2 known adipophilin adipose differentiationrelated protein commonly reported surface lipid droplets tissues hepatic lipids effectively induce Plin2 expression Plin2 inhibition increases insulin sensitivity reduces fatty liver 84 While perilipin 2antisense oligonucleotide Plin2ASO treatment decreases steatosis promotes proliferation fibrosis Furthermore Plin2ASO inhibits expression genes participate TG biosynthesis utilization including diac ylglycerol Oacyltransferase 2 acetyl coenzyme A carboxylase fatty acid oxidation carnitine palmitoyltransferase 1 suppressing transcription factors Additionally Plin2ASO therapy significantly decreases expression genes related cholesterol steroid metabolism reduces hepatic VLDL secretion increase insulin sensitivity 85 Choline Choline important phospholipid component present cell membranes ingested exogenously synthesized endogenously Choline methyl donors EXPERIMENTAL AND THERAPEUTIC MEDICINE 20 26 2020 5 synthesis phosphatidylcholine liver required synthesis secretion VLDL Therefore choline serves vital role liver lipid transport 86 Choline negative correlation NAFLD development affecting intracellular lipid metabolism muscle membrane lipid composition 87 Dietary choline metabolized intestinal microbiota converted trimethylamine resulting choline deficiency liver Choline deficiency hinders synthesis secretion VLDL leads accumulation TG liver promotes onset NAFLD Highfat diets lead formation intestinal microbiota convert dietary choline methylamines reducing circulating plasma levels phosphatidylcholine produce similar effects cholinedeficient diets causing NASH 88 Cholinedeficient diets establish animal models NASH 89 4 Amino acid metabolism NAFLD Impaired liver function leads imbalance amino acid homeostasis Amino acid metabolism extensively altered NAFLD involving branchedchain amino acids BCAAs aromatic amino acids AAAs methionine homocysteine arginine Additionally fatty liver associated deregu lated liver expression aminotransferases 90 The profiles amino acid metabolism gene sets evaluate hepatic oxidative stress patients NAFLD 91 BCAAs BCAAs amino acids nonlinear aliphatic sidechains include essential amino acids leucine valine isoleucine Cheng et al 92 reported increased serum BCAAs patients NAFLD Lake et al 91 demonstrated progression steatosis NASH serum leucine isoleucine valine levels significantly increased This increase associated liver fat accumulation early stages NAFLD BCAAs mediate numerous biological functions NAFLD Firstly BCAAs regulate glucose metabolism inducing insulin signaling 9394 Secondly increase lipolysis hyperlipidemia cause hepatic lipotoxicity leads inhibited autophagy hepatocytes 95 Thirdly BCAAs beneficial treating cirrhosis decreasing portal vein pres sure increasing mean artery pressure 96 Finally BCAAs induce higher branchedchain αketo acid dehydrogenase E1α expression levels skeletal muscles facilitates BCAA metabolism muscle tissue 97 Leucine supplementation demonstrated acti vate mammalian target rapamycin mediates cellular proliferation protein synthesis increases insulin sensitivity However leucine alleviates T2D exacerbates NAFLD making difficult use NAFLD treatment 98 AAAs AAAs class αamino acids aromatic rings include tryptophan phenylalanine tyrosine Celinski et al 99 demonstrated tryptophan substan tially attenuated levels proinflammatory cytokines improved certain parameters γglutamyl transferase triglyceride lowdensity lipoprotein lipid metabolism patients NAFLD Chen et al 100 reported serum phenylalanine concentration twofold higher patients NAFLD compared controls Furthermore Jin et al 101 investigated metabolic pathways altered association hepatic steatosis adolescents demonstrated plasma tyrosine levels positively correlated severity liver steatosis Phenylalanine catalyzed tyrosine phenylalanine hydroxylase liver metabolized 102 Presently mechanism AAA metabolic disorders NAFLD remains unclear A possible explanation tyrosine enters ketogenic pathway directly degraded acetyl coenzyme A ketogenic action 101 Therefore increased phenylalanine tyrosine intake contribute fat deposition liver Methionine homocysteine Methionine essential sulfurcontaining amino acid mainly metabolized liver 103 Homocysteine sulfhydrylcontaining amino acid produced catabolized primarily liver increased homocysteine concentrations event liver injury Alternatively elevated homocysteine conversely promote progression liver damage 104 Both methionine homocysteine associated NAFLD Methionine metabolism impacts methylation process leads production glutathione methylargi nines regulates homocysteine concentrations However methionine deficiency leads impaired methyltransferase antioxidative reactions elevated homocysteine 105 Increased homocysteine causes hyperhomocysteinemia alters intracellular lipid metabolism facilitate fat accumulation 106 Arginine Arginine antioxidant effects NASH inhibiting cytochrome P450 family 2 subfamily E member 1 activity decreasing TNFα antioxidant enzyme concentrations 107 Dogru et al 108 reported increased circulating asymmetric dimethylarginine early marker NAFLD Additionally Voloshin et al 109 synthesized novel chenodeoxycholic acidarginine ethyl ester conjugate treat NAFLD The conjugate reduces liver steatosis decreasing cholesterol blood glucose Aminotransferases Aminotransferases barometers liver health transport excessive amino acids circulation manage liver metabolic derangement associated severe gluconeogenesis IR 90 Aspartate amino transferase alanine transaminase γglutamyltransferase generally elevated NAFLD positively associated CIC2 expression liver 24110 5 Bile acid metabolism NAFLD Bile acid essential regulator hepatic fat glucose metabolism The concentration certain serum bile acids increase progression NAFLD including hydro phobic cytotoxic bile acids taurodeoxycholic acid taurocholic acid respectively 111 Bile acid metabolism obliterated NAFLD likely increased hepatic inflammatory signaling 112 Furthermore increased bile acid levels associated altered hepatic transport protein 6 SHAO et al ABNORMAL METABOLISM INVOLVED IN NAFLD multidrug resistance protein 3 expression NAFLD 113 The increased transcription bile acid synthesis pathway enzymes including sterol 12αhydroxylase bile acidCoAamino acid Nacyltransferase 25hydroxycholesterol7αhydroxylase indicates liver attempts ameliorate hepatotoxicity progression NAFLD 114 Farnesoid X receptor FXR Nuclear receptors NRs transcriptional factors sensitive environmental hormonal signals 115 The expression NRs FXR negative correlation NAFLD severity transcrip tional level 116 Schiöth et al 117 reported additional NAFLDinduced modulating effects type 2 diabetes associated altered composition concentrations bile acids continuous effect FXRdependent regulatory pathways FXRs abundantly expressed liver upregulation controls glucose lipid cholesterol bile acid homeostasis inflammation reduce NAFLD Firstly FXRs inhibit hepatic gluconeogenesis peripheral insulin sensitivity reduce plasma glucose concentrations Secondly FXRs suppress bile acid synthesis inhibiting cholesterol 7 αhydroxylase CYP7A1 ratelimiting enzyme synthesis bile acids cholesterol 118 The interaction bile acids FXRs leads reduction triglyc eride concentrations plasma consequence inhibits hepatic lipid deposition 119 Niemannpick c1like 1 NPC1L1 NPC1L1 reabsorbs cholesterol bile transports liver expressed bile duct membrane aggravating factor NAFLD 120 NAFLD exhibits oxidative stress leads increased freeradical activity lipid peroxidation increasing reactive oxygen species ROS ROS facilitate peroxidation lipids induction cytokines chemoattrac tion inflammatory cells HSC activation ultimately cause fibrosis extracellular matrix deposition 1 NPC1L1 resists oxidative stress endoplasmic reticulum stress ERS transporting free cholesterol hepatic cells modulating intracellular cholesterol content particularly mitochondria endoplasmic reticulum 121 Inhibiting NPC1L1 tually reduces cholesterol uptake induces recovery key molecules involved insulin signaling including Akt phosphorylation gluconeogenic enzymes 122 Bile acid transporters Bile acid transporters associated progression NAFLD 123 Nataurocholate cotransporting polypeptide NTCP influx bile acid trans porter participates reabsorption bile acids 124 As bile salt export pump NTCP effluent bile acid transporter exports bile acids Thus upregulation NTCP causes excessive bile acid concentrations hepatocytes ulti mately leads cell injury 116 Therefore blocking apical sodiumdependent bile acid transporter function improves NAFLD 125 Intestinal flora Intestinal ecological disruption NAFLD fully documented 126128 Intestinal flora medi ates detoxification bile acids conversion primary bile acid secondary bile acid species including lithocholic acid LCA deoxycholic acid Therefore inhibiting intestinal microbiota increases hepatic binding secondary bile acids leads increased burden secondary bile acid possible toxic effects Vitamin D attenuates toxic effects LCA biomarker noninvasive diagnosis NAFLD progression 126128 TrimethylamineNoxide TMAO gutfloradepen dent metabolite choline Chen et al 129 demonstrated increased risk fatty liver disease caused TMAO effect decreasing total bile acid levels pathways By decreasing synthesis bile acids inhibition key enzyme CYP7A1 limiting enterohepatic circulation bile acids liver intestines decreasing organic anion transporter multidrug resistance protein family protein expression 130 Therefore TMAO possibly affect hepatic TG levels reverse direction cholesterol transport glucose energy homeostasis altering synthesis transport bile acids indicating potential risk factor fatty liver disease 129 6 Iron metabolism NAFLD A total 30 patients NAFLD exhibit signs iron metabolism disorders 131 Iron metabolism disorders NAFLD commonly associated excess hepatic iron deficient serum iron NASH livers exhibit decreased transferrin transferrin receptor 2 132133 High dietary iron intake risk factor NAFLD Excess dietary iron leads hepatic oxidative stress inflammation hepatocel lular ballooning injury ultimately causes NASH 134 Moreover hepatic iron accumulation increases hepatic choles terol synthesis lipid deposition impaired hepatic cellular stress responses exacerbate NAFLD 135136 Iron serves substantial role occurrence oxidative stress catalyst ROS generation 137 Oxidative stress impairs mitochondrial function predisposes indi viduals impaired fatty acid oxidation eventually leads steatosis necrotizing inflammation cytokines TNFα IL6 IL8 malondialdehyde nitric oxide 138 Furthermore ROS induces trans ferrin decrease iron absorption interact iron induce IR inhibiting carbohydrate consumption altering function adipose tissue impacting release adipokines 132137 In NAFLD hepatic iron accumulation associated ferritin hepcidin human hemochro matosis protein impacting iron export import hepatocytes 131139 Ferritin Ferritin primary ironstorage protein majority tissues liver brain increased expression ferritin indicates iron overload tissues circulation Patients high ferritin severe NASH advanced fibrosis compared patients normal ferritin 140141 Ferritin decreased restricted calorie iron intake 142 Serum ferritin concentrations commonly elevated patients NAFLD increased iron stores fat content oxidative stress ERS systemic inflammation genetic background 143144 EXPERIMENTAL AND THERAPEUTIC MEDICINE 20 26 2020 7 Hepcidin Hepcidin main ironregulating peptide 145 Decreased hepcidin expression frequently observed patients NAFLD considered cause hepatic iron overload 146 Furthermore hepcidin suppresses iron influx diets efflux macrophages inhib iting ferroportin determining oxidative stress driving transformation macrophages foam cells 147 7 Conclusion In summary NAFLD associated imbalanced meta bolic network involves glucose lipids amino acids bile acids iron Among participating mechanisms underlying NAFLD lipid metabolism core metabolic process Lipid metabolism disorders directly lead lipid deposits Glucose linked lipids insulin abundant inefficiently processed NAFLD NAFLD exhibits hyperinsulinemia IR lead excess TG accumulation T2D respectively Additionally amino acids simultaneously regulate glucose lipid metabolism Bile acid associated glucose lipids FXRs choline Furthermore iron metabolism unique pathway iron accumulation induces ROS participate inflammation oxidative stress Oxidative stress increases lipid accumulation adding fatty acids cholesterol regulated NPC1L1 Metabolism NAFLD pathogenesis complex metabolic processes independent mutually contribute influence However previous studies mainly focus pathogenesis NAFLD single perspective facilitating separation factors originally interrelated It challenging conduct systematic integrated relevant studies draw corresponding conclusions Therefore investigation exploration detailed mechanism pathogenesis NAFLD necessary Given complex pathogenesis NAFLD single treat ment patients NAFLD discovered In future personalized treatment effective therapy NAFLD With additional indepth studies pathogenesis NAFLD effectively prevented treated future Acknowledgements Not applicable Funding The current study supported National Natural Science Foundation China grant 81873076 Shanghai Talents Development Fund Project grant 2017090 Availability data materials Not applicable Authors contributions MS wrote manuscript MS ZY YQ TW conducted research pathogenesis NAFLD TW supervised revised manuscript Ethics approval consent participate Not applicable Patient consent publication Not applicable Competing interests The authors declare competing interests References 1 Vanni E Bugianesi E Kotronen A De Minicis S YkiJärvinen H SvegliatiBaroni G From metabolic syndrome NAFLD vice versa Dig Liver Dis 42 320330 2010 2 Rinella ME Nonalcoholic fatty liver disease A systematic review JAMA 313 22632273 2015 3 Gawrieh S Marion MC Komorowski R Wallace J Charlton M Kissebah A Langefeld CD Olivier M Genetic variation peroxisome proliferator activated receptorgamma gene associated histologically advanced NAFLD Dig Dis Sci 57 952957 2012 4 Younossi ZM Koenig AB Abdelatif D Fazel Y Henry L Wymer M Global epidemiology nonalcoholic fatty liver diseasemetaanalytic assessment prevalence incidence outcomes Hepatology 64 7384 2016 5 Zhou J Zhou F Wang W Zhang XJ Ji YX Zhang P She ZG Zhu L Cai J Li H Epidemiological feature NAFLD 1999 2018 China Hepatology 71 18511864 2020 6 Marchisello S Di Pino A Scicali R Urbano F Piro S Purrello F Rabuazzo AM Pathophysiological molecular thera peutic issues nonalcoholic fatty liver disease An overview Int J Mol Sci 20 1948 2019 7 Bessone F Razori MV Roma MG Molecular pathways nonalcoholic fatty liver disease development progression Cell Mol Life Sci 76 99128 2019 8 Wasilewska N BobrusChociej A HarasimSymbor E Tarasów E Wojtkowska M Chabowski A Lebensztejn DM Increased serum concentration ceramides obese children nonalco holic fatty liver disease Lipids Health Dis 17 216 2018 9 Jegatheesan P De Bandt JP Fructose NAFLD The multifaceted aspects fructose metabolism Nutrients 9 230 2017 10 Chen L Chen XW Huang X Song BL Wang Y Wang Y Regulation glucose lipid metabolism health disease Sci China Life Sci 62 14201458 2019 11 Kim SH Kwon DY Kwak JH Lee S Lee YH Yun J Son TG Jung YS Tunicamycininduced ER stress accompanied oxidative stress abrogation sulfur amino acids metabolism liver Int J Mol Sci 19 4114 2018 12 Mouzaki M Wang AY Bandsma R Comelli EM Arendt BM Zhang L Fang S Fischer SE McGilvray LG Allard JP Bile acids dysbiosis nonalcoholic fatty liver disease PLoS One 11 e0151829 2016 13 Xu J Sun W Yang L Association iron metabolism cognitive impairment older nonalcoholic fatty liver disease individuals A crosssectional study patients Chinese center Medicine Baltimore 98 e18189 2019 14 Lim JS MietusSnyder M Valente A Schwarz JM Lustig RH The role fructose pathogenesis NAFLD metabolic syndrome Nat Rev Gastroenterol Hepatol 7 251264 2010 15 Jensen T Abdelmalek MF Sullivan S Nadeau KJ Green M Roncal C Nakagawa T Kuwabara M Sato Y Kang DH et al Fructose sugar A major mediator nonalcoholic fatty liver disease J Hepatol 68 10631075 2018 16 Alwahsh SM Gebhardt R Dietary fructose risk factor nonalcoholic fatty liver disease NAFLD Arch Toxicol 91 15451563 2017 17 Zhao S Jang C Liu J Uehara K Gilbert M Izzo L Zeng X Trefely S Fernandez S Carrer A et al Dietary fructose feeds hepatic lipogenesis microbiotaderived acetate Nature 579 586591 2020 8 SHAO et al ABNORMAL METABOLISM INVOLVED IN NAFLD 18 Zhang S Du T Zhang J Lu H Lin X Xie J Yang Y Yu X The triglyceride glucose index TyG effective biomarker identify nonalcoholic fatty liver disease Lipids Health Dis 16 15 2017 19 Khan RS Bril F Cusi K Newsome PN Modulation insulin resistance nonalcoholic fatty liver disease Hepatology 70 711724 2019 20 Omar BA Andersen B Hald J Raun K Nishimura E Ahrén B Fibroblast growth factor 21 FGF21 glucagonlike peptide 1 contribute diabetes resistance glucagon receptordeficient mice Diabetes 63 101110 2014 21 Patel V Joharapurkar A Kshirsagar S Sutariya B Patel M Patel H Pandey D Patel D Ranvir R Kadam S et al Coagonist GLP1 glucagon receptor ameliorates development nonalcoholic fatty liver disease Cardiovasc Hematol Agents Med Chem 16 3543 2018 22 Dongiovanni P Meroni M Baselli GA Bassani GA Rametta R Pietrelli A Maggioni M Facciotti F Trunzo V Badiali S et al Insulin resistance promotes lysyl oxidase like 2 induction fibrosis accumulation nonalcoholic fatty liver disease Clin Sci Lond 131 13011315 2017 23 Uygun A Kadayifci A Demirci H Saglam M Sakin YS Ozturk K Polat Z Karslioglu Y Bolu E The effect fatty pancreas serum glucose parameters patients nonalco holic steatohepatitis Eur J Intern Med 26 3741 2015 24 Fu D Cui H Zhang Y Lack ClC2 alleviates high fat dietinduced insulin resistance nonalcoholic fatty liver disease Cell Physiol Biochem 45 21872198 2018 25 Kumashiro N Erion DM Zhang D Kahn M Beddow SA Chu X Still CD Gerhard GS Han X Dziura J et al Cellular mechanism insulin resistance nonalcoholic fatty liver disease Proc Natl Acad Sci USA 108 1638116385 2011 26 Wu W Bi Y Tangsun Y Yin W Chen Y Zhu D Effects transcription factor sterol regulatory element binding protein1c palmitate acidinduced L6 cells insulin resistance mecha nism Zhonghua Yi Xue Za Zhi 95 611615 2015 In Chinese 27 Nakajima K Oda E Kanda E The association serum sodium chloride levels blood pressure estimated glomerular filtration rate Blood Press 25 5157 2016 28 Hong L Xie ZZ Du YH Tang YB Tao J Lv XF Zhou JG Guan YY Alteration volumeregulated chloride channel macrophagederived foam cell formation atheroscle rosis Atherosclerosis 216 5966 2011 29 Trevaskis JL Griffin PS Wittmer C NeuschwanderTetri BA Brunt EM Dolman CS Erickson MR Napora J Parkes DG Roth JD Glucagonlike peptide1 receptor agonism improves metabolic biochemical histopathological indices nonal coholic steatohepatitis mice Am J Physiol Gastrointest Liver Physiol 302 G762G772 2012 30 Bernsmeier C MeyerGerspach AC Blaser LS Jeker L Steinert RE Heim MH Beglinger C Glucoseinduced glucagonlike Peptide 1 secretion deficient patients nonalcoholic fatty liver disease PLoS One 9 e87488 2014 31 Chellali S Boudiba A Griene L Koceir EA Incretins adipocytokines interactions type 2 diabetic subjects nonalcoholic fatty liver disease Interest GLP1 glucagonlike peptide1 modulating biomarker Ann Biol Clin Paris 77 261271 2019 32 Thompson AM Trujillo JM Dulaglutide The newest GLP1 receptor agonist management type 2 diabetes Ann Pharmacother 49 351359 2015 33 Knop FK Brønden A Vilsbøll T Exenatide Pharmacokinetics clinical use future directions Expert Opin Pharmacother 18 555571 2017 34 Dong Y Lv Q Li S Wu Y Li L Li J Zhang F Sun X Tong N Efficacy safety glucagonlike peptide1 receptor agonists nonalcoholic fatty liver disease A systematic review metaanalysis Clin Res Hepatol Gastroenterol 41 284295 2017 35 Petit JM Vergès B GLP1 receptor agonists NAFLD Diabetes Metab 43 Suppl 1 2S282S33 2017 36 Ye DW Rong XL Xu AM Guo J Liveradipose tissue cross talk A key player pathogenesis glucolipid metabolic disease Chin J Integr Med 23 410414 2017 37 Li H Dong K Fang Q Hou X Zhou M Bao Y Xiang K Xu A Jia W High serum level fibroblast growth factor 21 independent predictor nonalcoholic fatty liver disease A 3year prospective study China J Hepatol 58 557563 2013 38 Zhou K Cen J The fatty liver index FLI incident hypertension A longitudinal study Chinese population Lipids Health Dis 17 214 2018 39 Emanuelli B Vienberg SG Smyth G Cheng C Stanford KI Arumugam M Michael MD Adams AC Kharitonenkov A Kahn CR Interplay FGF21 insulin action liver regulates metabolism J Clin Invest 124 515527 2014 40 Tucker B Li H Long X Rye KA Ong KL Fibroblast growth factor 21 nonalcoholic fatty liver disease Metabolism 101 153994 2019 41 Dongiovanni P Rametta R Meroni M Valenti L The role insulin resistance nonalcoholic steatohepatitis liver disease developmenta potential therapeutic target Expert Rev Gastroenterol Hepatol 10 229242 2016 42 Angulo P Kleiner DE DamLarsen S Adams LA Bjornsson ES Charatcharoenwitthaya P Mills PR Keach JC Lafferty HD Stahler A et al Liver fibrosis histologic features associated longterm outcomes patients nonalcoholic fatty liver disease Gastroenterology 149 389397e10 2015 43 GrauBové X RuizTrillo I RodriguezPascual F Origin evolution lysyl oxidases Sci Rep 5 10568 2015 44 Ikenaga N Peng ZW Vaid KA Liu SB Yoshida S Sverdlov DY MikelsVigdal A Smith V Schuppan D Popov YV Selective targeting lysyl oxidaselike 2 LOXL2 suppresses hepatic fibrosis progression accelerates reversal Gut 66 16971708 2017 45 Williamson KD Chapman RW New therapeutic strategies primary sclerosing cholangitis Semin Liver Dis 36 514 2016 46 Ibrahim SH Kohli R Gores GJ Mechanisms lipotoxicity NAFLD clinical implications J Pediatr Gastroenterol Nutr 53 131140 2011 47 Ferramosca A Zara V Modulation hepatic steatosis dietary fatty acids World J Gastroenterol 20 17461755 2014 48 Obara N Fukushima K Ueno Y Wakui Y Kimura O Tamai K Kakazu E Inoue J Kondo Y Ogawa N et al Possible involve ment mechanisms excess transfatty acid consumption severe NAFLD mice J Hepatol 53 326334 2010 49 Dongiovanni P Anstee QM Valenti L Genetic predisposi tion NAFLD NASH Impact severity liver disease response treatment Curr Pharm Des 19 52195238 2013 50 OrellanaGavaldà JM Herrero L Malandrino MI Pañeda A Sol RodríguezPeña M Petry H Asins G Van Deventer S Hegardt FG Serra D Molecular therapy obesity diabetes based longterm increase hepatic fattyacid oxidation Hepatology 53 821832 2011 51 Gastaldelli A Insulin resistance reduced metabolic flex ibility Cause consequence NAFLD Clin Sci Lond 131 27012704 2017 52 Poulsen MK Nellemann B Bibby BM StødkildeJørgensen H Pedersen SB Grønbaek H Nielsen S No effect resvera trol VLDLTG kinetics insulin sensitivity obese men nonalcoholic fatty liver disease Diabetes Obes Metab 20 25042509 2018 53 Assunção SNF Sorte NCAB Alves CAD Mendes PSA Alves CRB Silva LR Inf lammatory cytokines nonalcoholic fatty liver disease NAFLD obese children adolescents Nutr Hosp 35 7883 2018 54 Lopetuso LR Mocci G Marzo M DAversa F Rapaccini GL Guidi L Armuzzi A Gasbarrini A Papa A Harmful effects potential benefits antitumor necrosis factor TNFα liver Int J Mol Sci 19 2199 2018 55 Zahran WE Salah ElDien KA Kamel PG ElSawaby AS Efficacy tumor necrosis factor interleukin10 analysis followup nonalcoholic fatty liver disease progression Indian J Clin Biochem 28 141146 2013 56 Bocsan IC Milaciu MV Pop RM Vesa SC Ciumarnean L Matei DM Buzoianu AD Cytokines genotypephenotype correlation nonalcoholic steatohepatitis Oxid Med Cell Longev 2017 4297206 2017 57 Yang R Guan MJ Zhao N Li MJ Zeng T Roles extrahepatic lipolysis disturbance hepatic fatty acid metabolism TNFαinduced hepatic steatosis Toxicology 411 172180 2019 58 Jorge ASB Andrade JMO Paraíso AF Jorge GCB Silveira CM Souza LR Santos EP Guimaraes ALS Santos SHS DePaula AMB Body mass index visceral adipose tissue expression IL6 TNFalpha associated morphological severity nonalcoholic fatty liver disease individuals class III obesity Obes Res Clin Pract 12 Suppl 2 S1S8 2018 EXPERIMENTAL AND THERAPEUTIC MEDICINE 20 26 2020 9 59 Vida M Gavito AL Pavón FJ Bautista D Serrano A Suarez J Arrabal S Decara J RomeroCuevas M Rodríguez Fonseca F Baixeras E Chronic administration recombinant IL6 upregulates lipogenic enzyme expression aggravates highfatdietinduced steatosis IL6deficient mice Dis Model Mech 8 721731 2015 60 Romeo S HuangDoran I Baroni MG Kotronen A Unravelling pathogenesis fatty liver disease Patatinlike phospholipase domaincontaining 3 protein Curr Opin Lipidol 21 247252 2010 61 Romeo S Kozlitina J Xing C Pertsemlidis A Cox D Pennacchio LA Boerwinkle E Cohen JC Hobbs HH Genetic variation PNPLA3 confers susceptibility nonalco holic fatty liver disease Nat Genet 40 14611465 2008 62 Wang X Liu Z Wang K Wang Z Sun X Zhong L Deng G Song G Sun B Peng Z Liu W Additive effects risk alleles PNPLA3 TM6SF2 nonalcoholic fatty liver disease NAFLD Chinese population Front Genet 7 140 2016 63 Sookoian S Pirola CJ Metaanalysis influence I148M variant patatinlike phospholipase domain containing 3 gene PNPLA3 susceptibility histological severity nonalcoholic fatty liver disease Hepatology 53 18831894 2011 64 Aragonès G Auguet T Armengol S Berlanga A GuiuJurado E Aguilar C Martínez S Sabench F Porras JA Ruiz MD et al PNPLA3 expression related liver steatosis morbidly obese women nonalcoholic fatty liver disease Int J Mol Sci 17 630 2016 65 Zhang L You W Zhang H Peng R Zhu Q Yao A Li X Zhou Y Wang X Pu L Wu J PNPLA3 polymorphisms rs738409 nonalcoholic fatty liver disease risk related phenotypes A metaanalysis J Gastroenterol Hepatol 30 821829 2015 66 Rossi C Marzano V Consalvo A Zucchelli M Levi Mortera S Casagrande V Mavilio M Sacchetta P Federici M Menghini R et al Proteomic metabolomic character ization streptozotocininduced diabetic nephropathy TIMP3deficient mice Acta Diabetol 55 121129 2018 67 Pawlak M Lefebvre P Staels B Molecular mechanism PPARα action impact lipid metabolism inflammation fibrosis nonalcoholic fatty liver disease J Hepatol 62 720733 2015 68 Manzano León N Torres N Tovar AR Mechanism action sterol regulatory element binding proteins SREBPs cholesterol fattyacid biosynthesis Rev Invest Clin 54 145153 2002 In Spanish 69 Ziamajidi N Khaghani S Hassanzadeh G Vardasbi S Ahmadian S Nowrouzi A Ghaffari SM Abdirad A Amelioration chicory seed extract diabetes oleic acidinduced nonalcoholic fatty liver disease NAFLDnonalcoholic steatohepatitis NASH modulation PPARα SREBP1 Food Chem Toxicol 58 198209 2013 70 Park HS Jeon BH Woo SH Leem J Jang JE Cho MS Park IS Lee KU Koh EH Timedependent changes lipid metabo lism mice methionine choline deficiencyinduced fatty liver disease Mol Cells 32 571577 2011 71 Van Rooyen DM Farrell GC SREBP2 A link insulin resistance hepatic cholesterol inflammation NASH J Gastroenterol Hepatol 26 789792 2011 72 Adolph TE Grander C Grabherr F Tilg H Adipokines nonalcoholic fatty liver Disease Multiple interactions Int J Mol Sci 18 1649 2017 73 Gatselis NK Ntaios G Makaritsis K Dalekos GN Adiponectin A key playmaker adipocytokine nonalcoholic fatty liver disease Clin Exp Med 14 121131 2014 74 Ahmad A Ali T Kim MW Khan A Jo MH Rehman SU Khan MS Abid NB Khan M Ullah R et al Adiponectin homolog novel osmotin protects obesitydiabetesinduced NAFLD upregulating AdipoRsPPARα signaling obob dbdb transgenic mouse models Metabolism 90 3143 2019 75 Navekar R Rafraf M Ghaffari A AsghariJafarabadi M Khoshbaten M Turmeric supplementation improves serum glucose indices leptin levels patients nonalcoholic fatty liver diseases J Am Coll Nutr 36 261267 2017 76 Perfield JW II Ortinau LC Pickering RT Ruebel ML Meers GM Rector RS Altered hepatic lipid metabolism contributes nonalcoholic fatty liver disease leptindeficient ObOb mice J Obes 2013 296537 2013 77 ZelberSagi S Lotan R Shlomai A Webb M Harrari G Buch A Nitzan Kaluski D Halpern Z Oren R Predictors incidence remission NAFLD general population sevenyear prospective followup J Hepatol 56 11451151 2012 78 Polyzos SA Aronis KN Kountouras J Raptis DD Vasiloglou MF Mantzoros CS Circulating leptin nonalcoholic fatty liver disease A systematic review metaanalysis Diabetologia 59 3043 2016 79 Polyzos SA Kountouras J Mantzoros CS Leptin nonal coholic fatty liver disease A narrative review Metabolism 64 6078 2015 80 Liu Y Qiu DK Ma X Liver X receptors bridge hepatic lipid metabolism inflammation J Dig Dis 13 6974 2012 81 Rong X Albert CJ Hong C Duerr MA Chamberlain BT Tarling EJ Ito A Gao J Wang B Edwards PA et al LXRs regu late ER stress inflammation dynamic modulation membrane phospholipid composition Cell Metab 18 685697 2013 82 LimaCabello E GarcíaMediavilla MV MiquilenaColina ME VargasCastrillón J LozanoRodríguez T FernándezBermejo M Olcoz JL GonzálezGallego J GarcíaMonzón C SánchezCampos S Enhanced expression proinflammatory mediators liver Xreceptorregulated lipogenic genes nonalcoholic fatty liver disease hepatitis C Clin Sci Lond 120 239250 2011 83 Ni M Zhang B Zhao J Feng Q Peng J Hu Y Zhao Y Biological mechanisms related natural modulators liver X receptor nonalcoholic fatty liver disease Biomed Pharmacother 113 108778 2019 84 Tsai TH Chen E Li L Saha P Lee HJ Huang LS Shelness GS Chan L Chang BHJ The constitutive lipid droplet protein PLIN2 regulates autophagy liver Autophagy 13 11301144 2017 85 Imai Y Boyle S Varela GM Caron E Yin X Dhir R Dhir R Graham MJ Ahima RS Effects perilipin 2 antisense oligonucleotide treatment hepatic lipid metabolism gene expression Physiol Genomics 44 11251131 2012 86 Sherriff JL OSullivan TA Properzi C Oddo JL Adams LA Choline potential role nonalcoholic fatty liver disease case human bacterial genes Adv Nutr 7 513 2016 87 Michel V Singh RK Bakovic M The impact choline avail ability muscle lipid metabolism Food Funct 2 5362 2011 88 Suk KT Kim DJ Gut microbiota Novel therapeutic target nonalcoholic fatty liver disease Expert Rev Gastroenterol Hepatol 13 193204 2019 89 PradhanSundd T Vats R Russell JO Singh S Michael AA Molina L Kakar S Cornuet P Poddar M Watkins SC et al Dysregulated bile transporters impaired tight junctions chronic liver injury mice Gastroenterology 155 12181232e24 2018 90 Sookoian S Castaño GO Scian R Fernández Gianotti T Dopazo H Rohr C Gaj G San Martino J Sevic I Flichman D Pirola CJ Serum aminotransferases nonalcoholic fatty liver disease signature liver metabolic perturbations amino acid Krebs cycle level Am J Clin Nutr 103 422434 2016 91 Lake AD Novak P Shipkova P Aranibar N Robertson DG Reily MD LehmanMcKeeman LD Vaillancourt RR Cherrington NJ Branched chain amino acid metabolism profiles progressive human nonalcoholic fatty liver disease Amino Acids 47 603615 2015 92 Cheng S Wiklund P Autio R Borra R Ojanen X Xu L Törmäkangas T Alen M Adipose tissue dysfunction altered systemic amino acid metabolism associated nonalcoholic fatty liver disease PLoS One 10 e0138889 2015 93 Haufe S Witt H Engeli S Kaminski J Utz W Fuhrmann JC Rein D SchulzMenger J Luft FC Boschmann M Jordan J Branchedchain aromatic amino acids insulin resistance liver specific ectopic fat storage overweight obese subjects Nutr Metab Cardiovasc Dis 26 637642 2016 94 van den Berg EH FloresGuerrero JL Gruppen EG Borst MH WolakDinsmore J Connelly MA Bakker SJL Dullaart RPF Nonalcoholic fatty liver disease risk inci dent type 2 diabetes Role circulating branchedchain amino acids Nutrients 11 705 2019 95 Zhang F Zhao S Yan W Xia Y Chen X Wang W Zhang J Gao C Peng C Yan F et al Branched chain amino acids cause liver injury obesediabetic mice promoting adipocyte lipolysis inhibiting hepatic autophagy EBioMedicine 13 157167 2016 96 Li T Geng L Chen X Miskowiec M Li X Dong B Branchedchain amino acids alleviate nonalcoholic steatohepa titis rats Appl Physiol Nutr Metab 38 836843 2013 10 SHAO et al ABNORMAL METABOLISM INVOLVED IN NAFLD 97 Ra SG Miyazaki T Kojima R Komine S Ishikura K Kawanaka K Honda A Matsuzaki Y Ohmori H Effect BCAA supplement timing exerciseinduced muscle soreness damage A pilot placebocontrolled doubleblind study J Sports Med Phys Fitness 58 15821591 2018 98 Zarfeshani A Ngo S Sheppard AM Leucine alters hepatic glucoselipid homeostasis myostatinAMPactivated protein kinase pathwaypotential implications nonalcoholic fatty liver disease Clin Epigenetics 6 27 2014 99 Celinski K Konturek PC Slomka M CichozLach H Brzozowski T Konturek SJ Korolczuk A Effects treatment melatonin tryptophan liver enzymes parameters fat metabolism plasma levels cytokines patients nonalcoholic fatty liver disease14 months follow J Physiol Pharmacol 65 7582 2014 100 Chen Y Li C Liu L Guo F Li S Huang L Sun C Feng R Serum metabonomics NAFLD plus T2DM based liquid chromatographymass spectrometry Clin Biochem 49 962966 2016 101 Jin R Banton S Tran VT Konomi JV Li S Jones DP Vos MB Amino acid metabolism altered adolescents nonalcoholic fatty liver diseasean untargeted high resolution metabolomics study J Pediatr 172 1419e5 2016 102 Gaggini M Carli F Rosso C Buzzigoli E Marietti M Della Latta V Ciociaro D Abate ML Gambino R Cassader M et al Altered amino acid concentrations NAFLD Impact obesity insulin resistance Hepatology 67 145158 2018 103 Stojanović M Todorović D Šćepanović L Mitrović D Borozan S Dragutinović V LabudovićBorović M Krstić D Čolović M Djuric D Subchronic methionine load induces oxidative stress provokes biochemical histological changes rat liver tissue Mol Cell Biochem 448 4350 2018 104 Dai H Wang W Tang X Chen R Chen Z Lu Y Yuan H Association homocysteine nonalcoholic fatty liver disease Chinese adults A crosssectional study Nutr J 15 102 2016 105 Pacana T Cazanave S Verdianelli A Patel V Min HK Mirshahi F Quinlivan E Sanyal AJ Dysregulated hepatic methionine metabolism drives homocysteine elevation dietinduced nonalcoholic fatty liver disease PLoS One 10 e0136822 2015 106 Carvalho SC Muniz MT Siqueira MD Siqueira ER G omes AV Si lva K A Bez er r L C DA l meid V Oliveira CP Pereira LM Plasmatic higher levels homocysteine nonalcoholic fatty liver disease NAFLD Nutr J 12 37 2013 107 Abu Ser M M El Ga ma l BA ElKersh M A nd ElSaadani MA Investigation antioxidant role argi treatment protection intralipidinduced nonalcoholic steatohepatitis Lipids Health Dis 14 128 2015 108 Dogru T Genc H Tapan S Ercin CN Ors F Aslan F Kara M Sertoglu E Bagci S Kurt I Sonmez A Elevated asymmetric dimethylarginine plasma An early marker endothelial dysfunction nonalcoholic fatty liver disease Diabetes Res Clin Pract 96 4752 2012 109 Voloshin I HahnObercyger M Anavi S Tirosh O Larginine conjugates bile acidsa possible treatment nonalcoholic fatty liver disease Lipids Health Dis 13 69 2014 110 Chalasani N Younossi Z Lavine JE Diehl AM Brunt EM Cusi K Charlton M Sanyal AJ American Gastroenterological Association American Association Study Liver Diseases American College Gastroenterologyh The diag nosis management nonalcoholic fatty liver disease Practice guideline American gastroenterological associa tion American association study liver diseases American college gastroenterology Gastroenterology 142 15921609 2012 111 Chiang JYL Ferrell JM Bile acid metabolism liver pathobiology Gene Expr 18 7187 2018 112 Tanaka N Matsubara T Krausz KW Patterson AD Gonzalez FJ Disruption phospholipid bile acid homeo stasis mice nonalcoholic steatohepatitis Hepatology 56 118129 2012 113 Ferslew BC Johnston CK Tsakalozou E Bridges AS Paine MF Jia W Stewart PW Barritt AS IV Brouwer KL Altered morphine glucuronide bile acid disposition patients nonalcoholic steatohepatitis Clin Pharmacol Ther 97 419427 2015 114 Lake AD Novak P Shipkova P Aranibar N Robertson D Reily MD Lu Z LehmanMcKeeman LD Cherrington NJ Decreased hepatotoxic bile acid composition altered synthesis progressive human nonalcoholic fatty liver disease Toxicol Appl Pharmacol 268 132140 2013 115 Evans RM Mangelsdorf DJ Nuclear receptors RXR big bang Cell 157 255266 2014 116 Okushin K Tsutsumi T Enooku K Fujinaga H Kado A Shibahara J Fukayama M Moriya K Yotsuyanagi H Koike K The intrahepatic expression levels bile acid trans porters inversely correlated histological progression nonalcoholic fatty liver disease J Gastroenterol 51 808818 2016 117 Schiöth HB Boström A Murphy SK Erhart W Hampe J Moylan C Mwinyi J A targeted analysis reveals relevant shifts methylation transcription genes responsible bile acid homeostasis drug metabolism nonalcoholic fatty liver disease BMC Genomics 17 462 2016 118 Kim SG Kim BK Kim K Fang S Bile acid nuclear receptor farnesoid X receptor Therapeutic target nonal coholic fatty liver disease Endocrinol Metab Seoul 31 500504 2016 119 Martin IV Schmitt J Minkenberg A Mertens JC Stieger B Mullhaupt B Geier A Bile acid retention activation endogenous hepatic farnesoidXreceptor pathogenesis fatty liver disease obobmice Biol Chem 391 14411449 2010 120 Toyoda Y Ta kada T Yamanashi Y Suzuk H Pathophysiological importance bile cholesterol reabsorp tion Hepatic NPC1L1exacerbated steatosis decreasing VLDLTG secretion mice fed highfat diet Lipids Health Dis 18 234 2019 121 Yoshida M Novel role NPC1L1 regulation hepatic metabolism Potential contribution ezetimibe NAFLDNASH treatment Curr Vasc Pharmacol 9 121123 2011 122 Nomura M Ishii H Kawakami A Yoshida M Inhibition hepatic NiemannPick C1like 1 improves hepatic insulin resistance Am J Physiol Endocrinol Metab 297 E1030E1038 2009 123 AguilarOlivos NE CarrilloCórdova D OriaHernández J SánchezValle V PoncianoRodríguez G RamírezJaramillo M ChabléMontero F ChávezTapia NC Ur ibe M MéndezSánchez N The nuclear receptor FXR LXR upregulates bile acid transporter expression nonalcoholic fatty liver disease Ann Hepatol 14 487493 2015 124 Bechmann LP Kocabayoglu P Sowa JP Sydor S Best J Schlattjan M Beilfuss A Schmitt J Hannivoort RA Kilicarslan A et al Free fatty acids repress small heterodimer partner SHP activation adiponectin counteracts bile acidinduced liver injury superobese patients nonalco holic steatohepatitis Hepatology 57 13941406 2013 125 Rao A Kosters A Mells JE Zhang W Setchell KD Amanso AM Wynn GM Xu T Keller BT Yin H et al Inhibition ileal bile acid uptake protects nonalco holic fatty liver disease highfat dietfed mice Sci Transl Med 8 357ra122 2016 126 Chassa ing B Etien neMesm L nd Gewi r tz AT Microbiotaliver axis hepatic disease Hepatology 59 328339 2014 127 Houghton D Stewart CJ Day CP Trenell M Gut microbiota lifestyle interventions NAFLD Int J Mol Sci 17 447 2016 128 CastañoRodríguez N Mitchell HM Kaakoush NO NAFLD Helicobacter species intestinal microbiome Best Pract Res Clin Gastroenterol 31 657668 2017 129 Chen YM Liu Y Zhou RF Chen XL Wang C Tan XY Wang LJ Zheng RD Zhang HW Ling WH et al Associations gutfloradependent metabolite trimethylamineNoxide betaine choline nonalcoholic fatty liver disease adults Sci Rep 6 19076 2016 130 Koeth RA Wang Z Levison BS Buffa JA Org E Sheehy BT Britt EB Fu X Wu Y Li L et al Intestinal microbiota metabolism Lcarnitine nutrient red meat promotes atherosclerosis Nat Med 19 576585 2013 131 Datz C Müller E Aigner E Iron overload nonalcoholic fatty liver disease Minerva Endocrinol 42 173183 2017 132 Moya D Baker SS Liu W Garrick M Kozielski R Baker RD Zhu L Novel pathway iron deficiency pediatric nonalcoholic steatohepatitis Clin Nutr 34 549556 2015 EXPERIMENTAL AND THERAPEUTIC MEDICINE 20 26 2020 11 133 Tsuchiya H Ashla AA Hoshikawa Y Matsumi Y Kanki K Enjoji M Momosa k S Na kamuta M Ta ketomi A Maehara Y et al Iron state association retinoid metabolism nonalcoholic fatty liver disease Hepatol Res 40 12271238 2010 134 Handa P MorganStevenson V Maliken BD Nelson JE Washington S Westerman M Yeh MM Kowdley KV Iron overload results hepatic oxidative stress immune cell activation hepatocellular ballooning injury leading nonalcoholic steatohepatitis genetically obese mice Am J Physiol Gastrointest Liver Physiol 310 G117G127 2016 135 OBrien J Powell LW Nonalcoholic fatty liver disease Is iron relevant Hepatol Int 6 332341 2012 136 Tan TC Crawford DH Jaskowski LA Subramaniam VN Clouston AD Crane DI Bridle KR Anderson GJ Fletcher LM Excess iron modulates endoplasmic reticulum stressassociated pathways mouse model alcohol highfat dietinduced liver injury Lab Invest 93 12951312 2013 137 Fujita N Takei Y Iron overload nonalcoholic steatohepa titis Adv Clin Chem 55 105132 2011 138 Uysal S Armutcu F Aydogan T Akin K Ikizek M Yigitoglu MR Some inflammatory cytokine levels iron metab olism oxidan stress markers subjects nonalcoholic steatohepatitis Clin Biochem 44 13751379 2011 139 Aigner E Weiss G Datz C Dysregulation iron copper homeostasis nonalcoholic fatty liver World J Hepatol 7 177188 2015 140 Hagström H Nasr P Bottai M Ekstedt M Kechagias S Hultcrantz R Stål P Elevated serum ferritin associated increased mortality nonalcoholic fatty liver disease 16 years followup Liver Int 36 16881695 2016 141 Ghamarchehreh ME JonaidiJafari N Bigdeli M Khedmat H Saburi A Iron status metabolic syndrome patients nonalcoholic fatty liver disease Middle East J Dig Dis 8 3138 2016 142 Iwasa M Hara N Iwata K Ishidome M Sugimoto R Tanaka H Fujita N Kobayashi Y Takei Y Restriction calorie iron intake results reduction visceral fat serum alanine aminotransferase ferritin levels patients chronic liver disease Hepatol Res 40 11881194 2010 143 Kowdley KV Belt P Wilson LA Yeh MM Neuschwander Tetri BA Chalasani N Sanyal AJ Nelson JE NASH Clinical Research Network Serum ferritin independent predictor histologic severity advanced fibrosis patients nonal coholic fatty liver disease Hepatology 55 7785 2012 144 Valenti L Dongiovanni P Fargion S Diagnostic therapeutic implications association ferritin level severity nonalcoholic fatty liver disease World J Gastroenterol 18 37823786 2012 145 Boga S Alkim H Alkim C Koksal AR Bayram M Yilmaz Ozguven MB Tekin Neijmann S The relationship serum hemojuvelin hepcidin levels iron overload nonalco holic fatty liver disease J Gastrointestin Liver Dis 24 293300 2015 146 Tsuchiya H Ebata Y Sakabe T Hama S Kogure K Shiota G Highfat highfructose diet induces hepatic iron overload hepcidinindependent mechanism prior onset liver steatosis insulin resistance mice Metabolism 62 6269 2013 147 Valenti L Swinkels DW Burdick L Dongiovanni P Tjalsma H Motta BM Bertelli C Fatta E Bignamini D Rametta R et al Serum ferritin levels associated vascular damage patients nonalcoholic fatty liver disease Nutr Metab Cardiovasc Dis 21 568575 2011 This work licensed Creative Commons AttributionNonCommercialNoDerivatives 40 International CC BYNCND 40 License